IRIDEX (NASDAQ:IRIX) Major Shareholder Shih-Yao David Lin Acquires 10,000 Shares of Company Stock

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin bought 10,000 shares of IRIDEX stock in a transaction dated Thursday, October 16th. The stock was acquired at an average cost of $1.05 per share, with a total value of $10,500.00. Following the transaction, the insider owned 735,561 shares of the company’s stock, valued at $772,339.05. This trade represents a 1.38% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Stock Performance

IRIX stock opened at $0.88 on Thursday. IRIDEX Corporation has a 52 week low of $0.61 and a 52 week high of $1.65. The company has a market capitalization of $15.46 million, a PE ratio of -4.40 and a beta of 0.67. The company’s 50-day simple moving average is $0.73 and its 200 day simple moving average is $0.95.

IRIDEX (NASDAQ:IRIX) last issued its quarterly earnings data on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million for the quarter, compared to analyst estimates of $13.59 million. On average, analysts forecast that IRIDEX Corporation will post -0.12 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, IRIDEX has an average rating of “Hold” and a consensus target price of $3.00.

Key Stories Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: SEC disclosures show Lin made dozens of purchases totaling substantial share amounts, including transactions of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00. The repeated buying and growing ownership stake may be interpreted as a sign of confidence in IRIDEX’s long-term prospects. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: The filings also include purchases at prices ranging from approximately $0.84 to $1.52, with several individual transactions valued between roughly $20,000 and $58,000. This broad pattern of buying, rather than a single isolated trade, likely attracted speculative interest in the thinly traded stock. IRIDEX major shareholder acquires stock
• Neutral Sentiment: Investors should note that most purchases occurred weeks or months earlier, from March through June and in prior reporting periods; the disclosures are new, but the buying itself is not. The reports therefore provide sentiment support rather than evidence of a new operating development or immediate improvement in revenue and earnings.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down (LULD) pause, indicating that the stock’s rapid move exceeded permitted price bands. This highlights significant volatility and the potential for sharp reversals once trading resumes.

Institutional Trading of IRIDEX

Several large investors have recently modified their holdings of the stock. Bank of New York Mellon Corp bought a new position in shares of IRIDEX in the second quarter worth $29,000. Diversify Advisory Services LLC bought a new stake in IRIDEX during the second quarter worth about $30,000. Diversify Wealth Management LLC bought a new stake in IRIDEX during the first quarter worth about $35,000. United Capital Financial Advisors LLC bought a new stake in IRIDEX during the second quarter worth about $41,000. Finally, Thompson Davis & CO. Inc. grew its stake in IRIDEX by 66.5% during the first quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock worth $48,000 after buying an additional 18,944 shares in the last quarter. 20.10% of the stock is owned by institutional investors and hedge funds.

IRIDEX Company Profile

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.